Navigation Links
SpectraCell Laboratories Offers Additional Test for Heart Attack and Stroke Risk
Date:7/7/2008

HOUSTON, July 7 /PRNewswire/ -- SpectraCell Laboratories has added an innovative blood test called Lp-PLA2 (Lipoprotein-associated Phospholipase A2) to its arsenal of advanced cardiovascular testing aimed at early detection of cardiovascular disease. The new test measures the amount of a specific enzyme in blood that occurs when there is an active atherosclerotic process that could lead to the rupture of plaque and cause a heart attack or stroke.

Lipid measurement and cardiac imaging cannot identify which patients have rupture-prone plaque with thin fibrous caps. Therefore, finding serologic markers with high specificity for advanced plaque is a useful diagnostic tool in cardiovascular risk stratification. The Lp-PLA2 test helps physicians to identify patients who would benefit from more aggressive therapy and is especially recommended for intermediate and high-risk patients.

Once thought to be a simple process caused by the deposition of too much cholesterol in the arteries, atherosclerosis now appears to be a condition where the arterial lesions are inflamed, eventually leading to plaque rupture causing a heart attack or stroke. Lp-PLA2 is associated with a doubling of cardiovascular risk.

"What makes Lp-PLA2 so unique is that it is very specific to vascular inflammation, making it an excellent indicator of active atherosclerosis, which is otherwise difficult to detect through conventional methods," states Dr. Jan Troup, Ph.D., Director of Lipid Science at SpectraCell. "It tells a doctor that the risk of MI or stroke is higher due to developing vulnerable plaque. Doctors can use this information to modify treatment strategies determined by lipoprotein particles alone."

Since stroke is the leading cause of disability and third leading cause of death in America, early detection and prevention is key, especially since 68% of heart attacks and strokes occur from blood clots, not narrowing of the arteries.

Although Lp-PLA2 is an inflammatory marker, it is not affected by inflammation that might occur from infection or injury. This makes Lp-PLA2 a more specific marker than the more familiar CRP (C-Reactive Protein) which can be elevated from systemic infection, even when the vascular walls are healthy. High Lp-PLA2 in combination with high hs-CRP increases the risk level four fold.

Since 50% of all heart attacks occur in patients with normal cholesterol values, the Lp-PLA2 test is often used in conjunction with advanced lipoprotein tests. SpectraCell's LPP+(TM) combines advanced cholesterol testing with additional independent risk factors such as Lp-PLA2, hs-CRP, insulin and homocysteine. It is typically covered by standard insurance and Medicare.

About SpectraCell Laboratories -- SpectraCell is a CLIA accredited laboratory that services healthcare providers nationwide by providing advanced clinical testing with the patent pending LPP(TM) (Lipoprotein Particle Profile) and FIA(TM) (Functional Intracellular Analysis) and tests.

SpectraCell's LPP(TM) testing is the most advanced lipoprotein test available. Unlike traditional cholesterol tests, SpectraCell's LPP(TM) directly measures the number of several classes of lipoprotein particles providing an accurate assessment of cardiovascular risk.

SpectraCell's FIA(TM) testing is an innovative assessment of a patient's nutritional status. Unlike traditional serum, hair and urine tests, SpectraCell's FIA(TM) measures how an individual's white blood cells function in specific nutritional environments. Over 30 vitamins, minerals, amino acids and antioxidants are evaluated. As a result, individual differences in metabolism, age, genetics, health, prescription drug usage, absorption rate and other factors are taken into consideration.


'/>"/>
SOURCE SpectraCell Laboratories
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Dr. Wei Sun, PhD, MD Joins SpectraCell Laboratories
2. Mesa Laboratories, Inc. Added to the Russell Microcap Index
3. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Elavil(R)
4. Birchwood Laboratories Expands B-SURE™ Incontinence and Personal Care Product Line™; Three New Products Added Including B-SURE Fresh 'n Go™, B-SURE Bottom Balm™ and B-SURE Traveler™
5. Roxane Laboratories, Inc. Announces the Launch of Ramipril Capsules
6. Nordic Naturals, Carlson Laboratories and Metagenics Announce Dismissal of Patent Infringement and Unfair Competition Suit
7. IDEXX Laboratories to Present at William Blair 28th Annual Growth Stock Conference
8. Advanced Instruments Anoxomat Mark II Anaerobic System is Excellent Alternative to Anaerobic Chambers, Gas Bags in Clinical Laboratories
9. Caraco Pharmaceutical Laboratories, Ltd. Reports Record Results for the Fourth Quarter and Fiscal Year 2008
10. Caraco Pharmaceutical Laboratories, Ltd. to Announce Fourth Quarter and Fiscal Year 2008 Results on May 29, 2008
11. Quest Diagnostics Chooses Roches Fully Automated, Real-Time HIV-1 Viral Load Monitoring Test For Its Customers in Laboratories Nationwide
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... ... 2017 , ... Texas Physical Therapy Specialists (TexPTS) is pleased to announce ... The clinic is the group’s 7th location in San Antonio and 23rd in Texas. ... provide care from the clinic, which opened March 22, 2017. , The ...
(Date:3/24/2017)... ... March 24, 2017 , ... ... related services to families and business owners across eastern Michigan, is connecting with ... families struggling with financial difficulties. , The Oxford/Orion FISH Food Pantry works to ...
(Date:3/24/2017)... ... March 24, 2017 , ... In just ... EcoQube Frame vertical micro-veggies garden on Kickstarter . Surpassing the $100,000 milestone ... with nearly 2,000 consumers (and counting) already backing the campaign. , “We ...
(Date:3/24/2017)... (PRWEB) , ... March 24, 2017 , ... ... Assili, announce that they are now offering treatments for sleep apnea and TMJ ... dental offices. Sleep apnea , specifically the obstructive type, is increasingly being ...
(Date:3/24/2017)... ... 24, 2017 , ... The law firm of Enea, Scanlan & Sirignano, ... Westchester resident Lauren C. Enea has joined the firm as an associate attorney. Ms. ... practice in elder law, Medicaid planning and applications, and Wills, Trusts and Estates. ...
Breaking Medicine News(10 mins):
(Date:3/24/2017)... SAN DIEGO , March 24, 2017  GenomeDx ... (Genomics Resource Information Database) and Decipher® Prostate Cancer Classifier ... Annual European Association of Urology (EAU) Congress held March ... . The Annual EAU Congress is ... and most comprehensive research in the urological field. ...
(Date:3/24/2017)... , March 23, 2017  HealthMine surveys with ... 2017 revealed that health plan members want help from ... to stay engaged in their health, 2) help closing ... integrated platform for health and 5) relevant, real-time guidance. ... and lowering healthcare costs. A ...
(Date:3/24/2017)...  Provectus Biopharmaceuticals, Inc. (OTCQB: PVCT, www.provectusbio.com ... and dermatology biopharmaceutical company, today disclosed terms of ... (the "Definitive Financing") it entered into on March ... who are referred to in the Definitive Financing ... with the Securities and Exchange Commission.   ...
Breaking Medicine Technology: